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INTRODUCTION  
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Bone mass is controlled by the actions of osteoclasts which degrade bone and 
osteoblasts with form new bone.  Osteoporosis is a pathologic condition of bone 
commonly associated with aging in males and females, and is accelerated in women 
following menopause.  After menopause, the bone resorbing activity of osteoclasts 
exceeds bone formation by osteoblasts, resulting in decreased trabecular and cortical 
bone mass.  Reduced bone mass increases the risk of pathologic fracture of bones.   
One of the major hormones regulating bone mass is estrogen.  Estrogen plays a 
role in regulating bone remodeling by controlling remodeling activation, osteoblast and 
osteoclast numbers, and their respective effectiveness in bone formation and resorption, 
respectively.  As a result of declining estrogen levels after menopause, the elegant 
balance between the actions of osteoclasts and osteoblasts is altered, and bone resorption 
exceeds bone formation, resulting in bone loss and increased bone fragility.  However, 
the intracellular proteins that control the effects of estrogen on bone cell function are not 
completely understood.   
Pyk2 is a protein tyrosine kinase that plays an important role in regulating bone 
resorption by osteoclasts [1, 2] as well as osteoblast proliferation and differentiation [3, 
4].  Deletion of the Pyk2 gene in mice leads to an increase in bone mass, in part due to 
dysfunctional osteoclast and osteoblast activity  [1, 3].  However, the mechanism of 
action of Pyk2 and its role in estrogen signaling is unknown.  Moreover, the role of Pyk2 
in the protection of bone loss associated with menopause is unclear.  The aim of this 
study was to examine the role of Pyk2 in a mouse model of post-menopausal bone loss 
using ovariectomized (OVX) wild type (WT) and Pyk2 KO mice.   
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PURPOSE OF THE STUDY 
 The purpose of the study was to examine and compare the effects of ovariectomy 
with or without estrogen supplementation on trabecular and cortical bone mass in Pyk2 
KO and WT mice. 
 
HYPOTHESIS 
• Pyk2 KO mice will have higher bone mass after ovariectomy than WT mice.  
• Ovariectomized Pyk2 KO mice supplemented with estrogen will have increased 
bone density compared to WT ovariectomized mice supplemented with estrogen. 
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Osteoporosis is a pathologic condition of bone that leads to decreased bone mass, 
increased fragility of bone, and increased risk of pathologic fracture of bone.  Nearly half 
of all women and one fifth of all men will have an osteoporotic-related fracture in their 
lifetime, contributing to 1.5 million osteoporotic fractures annually [5, 6]. Current 
standards of care utilize drugs known as bisphosphonates to inhibit the activity of 
osteoclasts which resorb bone, anabolic pharmaceutical agents such as parathyroid 
hormone that stimulate bone formation by osteoblasts, and selective estrogen receptor 
modulators which act selectively at estrogen receptors as agonists or antagonists in 
various tissues to prevent bone loss [7].  Historically, estrogen replacement therapy was 
prescribed to prevent post-menopausal bone loss, but due to elevated risk of stroke, blood 
clots, breast and uterine cancer, this therapeutic approach is on the decline [7].  Despite 
these medical interventions, fracture rates are only reduced by approximately 50-70% and 
treatments are not without untoward side effects [8, 9].  Bisphosphonates have been 
shown to be associated with rare but significant side effects such as pathologic fractures, 
osteonecrosis of the jaw, and other concomitant adverse effects [10].  Recombinant 
parathyroid hormone such as teriparatide has been linked with osteosarcoma in 
preclinical animal studies, so two year usage limits have been applied to this drug [11]. 
Selective estrogen receptor modulators (SERMs) such as raloxifene, though promising in 
reducing vertebral fractures, were associated with side effects such as hot flashes, leg 
cramps as well as deep vein thrombosis and pulmonary embolisms [7]  Therefore, 
research scientists and medical professionals continue to pursue alternative forms of 
treatment for bone loss associated with osteoporosis.  
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 Bone mass is controlled by genetic factors, diet, hormones, cytokines, mechanical 
loading, as well as other environment conditions [12, 13].  The steroid hormones, 
estrogen and testosterone, are critical for bone mass homeostasis, and depletion of either 
hormone leads to decreased bone mass and elevated risk of osteoporosis [12].  Estrogen 
controls bone remodeling through hormonal signaling pathways (Figure1) [14].  Estrogen 
produced by the ovaries is stimulated by follicle stimulating hormone (FSH) which is 
secreted from the pituitary gland. A negative feedback loop produced by elevated 
estrogen levels controls FSH secretion and is modulated by the pituitary gland. When 
estrogen levels are reduced, FSH secretion is increased and production of cytokines by 
the bone marrow and immune cells is increased. These cytokines promote osteoclast 
differentiation from hematopoietic precursors found in bone marrow.  Estrogens and 
growth hormone from the pituitary gland also prompt hepatic production of insulin-like 
growth factor 1 (IGF1) that stimulates osteoblast differentiation [14]. Both males and 
females are affected by hormone-related bone loss, but females are more dramatically 
affected due to estrogen depletion after menopause [12].  Bone loss in females occurs in 
two stages [12].  During the first stage, trabecular bone is predominantly lost due to 
increased osteoclast-mediated bone resorption; whereas, during the second phase of 
menopause which occurs four to eight years later, loss of both trabecular and cortical 
bone occurs, mostly attributed to decreases in bone formation [12].  
In adults, bone density is maintained by balancing the activity of osteoblasts 
which form new bone, and osteoclasts, which degrade bone.  These two cell types 
compose the bone multi-cellular unit, a tightly coupled functional unit where both cells 
types communicate.  The mechanism of bone remodeling within the bone multi-cellular 
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unit is initiated by osteoclasts whose catabolic activity degrades the mineralized bone.  
The control of osteoclast differentiation and number is controlled by osteoblasts, which 
release macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear 
factor κB ligand (RANKL).  RANKL binds to the RANK receptor on osteoclast 
progenitor cells, and with the combined actions of M-CSF, will lead to an increase in 
osteoclast numbers.  The osteoclastogenic effects of RANKL are blocked by 
osteoprotegerin (OPG) which is also secreted by osteoblasts and acts as a decoy receptor 
for RANKL.  Osteoblasts embedded in the mineralized bone matrix further differentiate 
to become osteocytes which play a role in mechano-signaling and mechano-transduction 
[15].  Recently, it was also shown that osteoclast differentiation is regulated by osteocyte-
derived M-CSF, RANKL and OPG [16-18].  Therefore, the local ratio of RANKL/OPG, 
whether secreted by osteoblasts or osteocytes, helps keep osteoclast numbers in check by 
decreasing the ability of RANKL to bind to its receptor on early osteoclasts [12, 19].  
Following bone resorption, osteoclast die by apoptosis and osteoblast precursor cells are 
recruited to the resorbed site, possibly by growth factors released from the degraded 
bone.  The osteoblastic precursors undergo differentiation into mature osteoblasts that 
secrete un-mineralized osteoid which is later mineralized to form new bone [12, 16, 19].  
Under normal homeostatic conditions, the amount of bone formed at a given site closely 
approximates the amount resorbed.  
Estrogen depletion affects the bone cells in different ways.  Estrogen depletion 
increases the proliferation of the osteoblast cell lineage, which regulates 
osteoblastogenesis and bone formation [20-24].  However, osteoblasts have reduced 
ability to form new bone, offsetting the balance in favor of bone resorption at each 
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remodeling site.  This results in a decrease in bone mass [12].  Estrogen negatively 
affects osteoclasts at the receptor level by decreasing bone resorbing activity [25, 26] and 
inducing osteoclast apoptosis [12, 27].  With declining estrogen levels after menopause, 
the regulatory control of osteoclast numbers and activity is removed.  This promotes 
osteoclast differentiation, leading to increased numbers of osteoclasts, increased bone 
resorption and subsequently to a decrease in bone mass and bone strength.  Estrogen-
deficiency also promotes osteoclast survival which is the predominant means of 
increasing osteoclast numbers after menopause [24, 28].  
The actions of estrogen are mediated by binding to its receptors, estrogen receptor 
alpha (ERα) and estrogen receptor beta (ERβ).  ERα and ERβ are differentially expressed 
in various skeletal and non-skeletal tissues. In the skeleton, ERα is found predominantly 
in cortical bone and ERβ is expressed in trabecular bone [29, 30]. ERα expression is 
increased during osteoblast differentiation of pre-osteoblasts, whereas ERβ levels remain 
relatively constant throughout differentiation [29].  ERα and ERβ have compensatory 
actions on skeletal bone mass in female mice, and both influence bone remodeling.  
However, in male mice, ERα appears to have a more predominant effect on bone 
remodeling [31].  The activation of the ERs in bone cells also activates a number of other 
signaling cascades which are important for cellular function [32-35].  ERs can activate 
signaling through the nucleus or cytoplasm.  Nuclear signaling is the classical pathway of 
estrogen signaling and it can take 30 to 60 minutes to affect changes in gene expression 
[36].  In the classical nuclear activation pathway of osteoblasts, circulating estrogen binds 
to ERα, which is subsequently translocated to the nucleus where it acts as a nuclear 
transcription factor [37, 38] and promotes expression of proteins such, c-fos, c-jun, jun-
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D, which have important effects in osteoblasts [24, 28, 39].  In addition, estrogen leads to 
increased secretion of Fas ligand (FasL) by osteoblasts, which subsequently binds to the 
pro-apoptotic Fas receptor on osteoclasts.  This promotes osteoclast apoptosis and 
decreases osteoclast cell number [24, 27, 28, 39-42].  Alternatively, estrogen can act in 
the cytoplasm to activate proteins such as receptor tyrosine kinases that result in rapid 
intracellular responses.  Examples of these non-canonical estrogen signaling pathways 
are activation of mitogen-activated protein kinases, adenylyl cyclase and G-protein 
coupled receptors [36, 43].   
Estrogen binding to ERα also initiates a signaling cascade involving the focal 
adhesion kinase (FAK) and other proteins [44].  It was previously established that 
estrogen depletion reduces breast cancer cell motility via FAK [44] and that ERα 
promotes endothelial cell motility through FAK [45, 46].  The tyrosine kinase Pyk2 is 
highly-related to FAK at the nucleotide and amino acid level.  However, Pyk2 is 
expressed predominantly in neural and hematopoietic tissues, whereas FAK is expressed 
more ubiquitously [47].  The role of Pyk2 in estrogen signaling is unclear.  In one study, 
it was shown that 17β-estradiol stimulation of platelet cells induced the translocation and 
activation of Pyk2 [48], which is mediated by activation of ERβ and the integrin αiibβ3 
[49].   
Deletion of Pyk2 in mice leads to osteopetrosis (increased bone mass) as a result 
of defective osteoclast activity and increased osteoblastic bone formation [1, 3].  Pyk2 
influences osteoclast differentiation and bone resorption by interacting with various 
protein signaling cascades involved in osteoclast cell movement and bone resorbing 
activity [2, 50, 51].  Several groups have reported that Pyk2 is localized to actin-rich 
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adhesion structures called podosomes in osteoclasts, which are organized as a ring-like 
structure around the cell periphery [27, 52].  Upon cell attachment and integrin activation 
[53], Pyk2 associates with several proteins associated with actin ring formation, including 
p130CAS [54], Src [52], Cbl [55], integrins [52], gelsolin [56], and paxillin [57].   
Pyk2 also plays a role in osteoblast function [3, 53, 58].  By quantification of a 
fluorochrome label, which integrates into actively mineralizing bone, it was demonstrated 
that Pyk2 KO mice have a 139% increase in bone formation rate in tibia from compared 
to wild-type mice [3]. This increase was the result of both increased mineralizing surface 
per bone surface and mineral apposition rate. In addition, it has been reported that bone 
marrow cells from Pyk2 KO mice cultured in osteogenic media containing ascorbic acid 
and β-glycerolphosphate exhibit elevated alkaline phosphatase levels, a marker of 
osteoblast activity [3, 59].  Importantly, unpublished studies from Dr. Bruzzaniti’s 
laboratory revealed that deletion of Pyk2 results in a much greater increase in bone mass 
in female mice compared to males.  Moreover, Pyk2 was found to form a molecular 
complex with the ERs in calvarial-derived osteoblasts in vitro.  Together, these studies 
suggest that Pyk2 plays a role in regulating osteoclast and osteoblast activity.  
Furthermore, these studies support a potential role for Pyk2 in regulating estrogen 
receptor signaling in bone cells.   
 In the current study, we examined the role of Pyk2 in the maintenance of bone 
mass in estrogen-depleted and estrogen-replete female mice.  To determine the role of 
Pyk2 in the regulation of bone mass, we compared femoral bone morphometrics in WT 
and global Pyk2 KO mice following ovariectomy or sham surgeries.  We hypothesized 
that deletion of the Pyk2 gene in mice which increases bone mass, would confer a 
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protective effect against bone loss in ovariectomized mice compared to WT mice.  We 
also proposed that estrogen supplementation would rescue bone loss in ovariectomized 
mice, and increase the magnitude of the bone mass response in Pyk2 KO mice.   
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MATERIALS AND METHODS 
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Pyk2 KO Mice: The IACUC approval number is DS000885R and the biohazard 
approval number is 1085.  Pyk2 KO mice have been backcrossed >15 generations onto a 
C57Bl6 background.  Mice were bred as heterozygotes and crossed to generate knockout 
mice and wild-type littermates. 
 
Ovariectomy:  OVX was performed on 12 week old WT and Pyk2 KO female mice. 
Sixty mice were divided into six groups of 10 that are wild type or Pyk2 KO, and groups 
were treated with sham surgery (ovaries are gently lifted and replaced into the abdominal 
cavity), OVX plus placebo implant, or OVX plus estrogen pellet implantation.  For OVX, 
mice were given a subcutaneous pre-operative dose of the analgesic buprenorphine (1-.5 
mg/kg), and anesthetized using inhaled isoflurane. After shaving, a small dorsal incision 
was made 1-2 cm lateral to the midline and below the last rib. The cutting point of the 
ovaries was tied with Ethicon coated vicryl braided polygalactan 910 absorbable sutures, 
and the organs were removed using scissors or a scalpel.  Estrogen (E2) releasing pellets 
were placed at the time of surgery subcutaneously in a dorsal location for 4 weeks into 
two of the groups, the estrogen replacement dose of 167 ng 17β-estradiol/mouse/day 
(Innovate Research of America, Sarasota, Florida, USA).  The estrogen pellet 
supplementation was used to replicate hormone replacement therapy following 
menopause, and to determine the resultant effects of estrogen on bone mass after OVX in 
WT and Pyk2 KO mice.  The peritoneum was closed with a few sutures and skin closed 
with wound clips.  Mice were housed for 28 days post-surgery, food and water ad 
libetum, and sacrificed at 16 weeks of age. To reduce postoperative pain, analgsia 
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(Buprenorphine 0.05-0.1 mg/kg SQ every 12 hours)  was provided for two days or for as 
long as deemed necessary by veterinary staff.   
 
Micro-computed Tomography:  After euthanization by inhaled isoflurane and cervical 
dislocation, posterior legs were amputated and stored in formalin.  All soft tissue was 
removed from bone, and the femur was separated from the tibia and fibula and stored in 
70% ethanol.  Uterine wet weight of mice was also recorded at necropsy to the nearest 
milligram.  Micro-computed tomography (micro-CT) studies were performed on the 
distal femoral metaphysis and cortical diaphysis using the Skyscan 1172 high-resolution 
desk-top micro-CT system (Skyscan, Aartselaar, Belgium).  Samples were wrapped in 
parafilm (Brand, Germany), and affixed to the scanning stage.  Scans were acquired using 
an x-ray source set at 60kV over an angular range of 180 degrees (rotational steps of 0.7 
degrees) with a 6 µm pixel size.  Projection images were reconstructed using standard 
Skyscan software (NRecon, Skyscan).  The trabecular bone of the distal femora 
secondary spongiosa was segmented from the cortical shell for 1mm of tissue (165 slices) 
beginning at the point where the femoral condyle disappears and the cortex is relatively 
intact and moving proximally (Figure 2A).  A single slice of cortex was analyzed at a site 
3mm proximal from the trabecular region.  Trabecular site outcomes included bone 
volume/total volume (BV/TV), trabecular number (Tb.N), and trabecular thickness 
(Tb.Th).  Cortical parameters included mean total cross-sectional bone area (Ct.Ar), 
cortical thickness (Ct.Th), and mean polar moment of inertia (CSMI polar). 
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Serology:  In addition to bone analyses, at necropsy serum was collected and uterine wet 
weight measured, as a measure of effectiveness of estrogen-depletion and estrogen-
replacement.  For serum collection, animals fasted for 12 hours prior to blood draw.  
Blood was collected and stored in a glass tube for 30 to 60 minutes at room temperature, 
and then the clot was separated from the walls of the tube to allow for clot contraction.  
After overnight storage at 4°C, the clot was removed and the sample centrifuged at 2000 
to 3000 rpm for 10 minutes and stored at -80°C.  Serum levels of circulating estradiol in 
WT and Pyk2 KO mice was measured using commercially available enzyme-linked 
immunosorbant assays (ELISA) (Calbiotech #ES180S-100). 
 
Statistical analysis:  The effects of Pyk2-KO and estrogen status (sham, OVX+Placebo, 
OVX+estrogen) and their interaction the bone parameters were analyzed using two-way 
ANOVA, with Tukey's multiple comparisons procedure used to control the overall 
significance level of the pair-wise comparisons at 5%. Distributions of the outcomes were 
examined, and transformations of the data were necessary for the analyses: natural 
logarithm of the trabecular bone parameters and cortical mean polar moment of inertia 
and the ranks of cortical bone parameters were used for the analyses. Our group sizes had 
sufficient power (>0.80) to detect a 13.6% difference between any two groups. 
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RESULTS 
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ROLE OF PYK2 ON TRABECULAR BONE  
 
To assess the role of Pyk2 on the regulation of bone mass in response to estrogen 
status, we performed OVX or sham surgeries on 12 week old female WT and Pyk2 KO 
mice.  One group of mice for each genotype also received OVX surgery plus estrogen 
supplementation (Table 1).  After 4 weeks, we performed micro-CT analysis of the distal 
femoral metaphysis of mice to examine the effects of estrogen and/or Pyk2 status on 
trabecular bone mass and bone geometry.  Specifically, we quantified changes in bone 
volume to total volume (BV/TV), trabecular thickness (Tb.Th) and trabecular number 
(Tb.N).   
Micro-CT analysis revealed a higher overall bone mass in Pyk2 KO mice than 
WT mice as expected.  Micro-CT analysis also revealed a higher bone mass in Pyk2 KO 
OVX mice compared to WT OVX mice.  Representative micro-CT images of our study 
groups are shown in Figure 2.  The mean ± standard deviation (SD) of the trabecular data 
is shown in Table 2 and graphically in Figure 3.  Analysis of our findings revealed a 
drastic difference between sham WT and Pyk2 KO mice for BV/TV, Tb.Th, and Tb.N 
(Figure 3A-D).  Similarly, Pyk2 KO OVX and OVX+E2 mice had higher BV/TV, Tb.Th 
and Tb.N than WT OVX and WT OVX+E2 groups, respectively.  Overall, there was a 
significant effect of OVX on trabecular bone parameters, with lower BV/TV values in 
OVX animals compared to sham when all genotypes and groups were combined (Table 
3).  However, in both WT and Pyk2 KO mice, we did not find a statistically significant 
decrease in BV/TV between sham and OVX surgery groups (Table 4).  This can possibly 
be explained by an unexpectedly high standard deviation, insufficient animal numbers or 
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not allowing enough time to pass after OVX surgery to produce statistically significant 
differences in bone geometry.  In contrast, there was significantly higher trabecular 
BV/TV, Tb.Th, and Tb.N after estrogen supplementation, compared to sham or OVX 
mice for both Pyk2 KO and WT mice (Figure 3A-C and Table 4).   
We next examined if the difference in BV/TV between OVX+E2 and OVX was 
statistical significant between Pyk2 and WT mice.  For these studies, we calculated the 
difference (delta) for Pyk2 KO mice versus WT mice for all trabecular parameters using 
the analysis (OVX+E2 minus OVX).  The results are shown in Table 5.  These analyses 
revealed that the magnitude of the BV/TV, Tb.Th and Tb.N response in Pyk2 KO mice 
after estrogen supplementation was significantly greater than the effects of estrogen on 
BV/TV Tb.Th and Tb.N in WT mice.  That is, there was a greater increase in trabecular 
bone parameters for Pyk2 KO mice than WT mice following estrogen supplementation in 
OVX mice.  Together, these findings reveal that Pyk2 KO sham, OVX and OVX+E2 
mice have higher trabecular bone mass than WT sham, OVX or OVX+E2 mice, 
respectively.  In addition, Pyk2-KO mice appear to respond better to the effects of 
estrogen supplementation than WT mice, resulting in a greater increase in bone mass. 
 
ROLE OF PYK2 ON CORTICAL BONE  
 
We next examined the effect of Pyk2 on cortical area (Ct.Ar), cortical thickness 
(Ct.Th), and polar cross-sectional moment of inertia (CSMI).  In both Pyk2 KO and WT 
mice, we found that estrogen depletion (OVX mice) did not affect Ct.Th, Ct.Ar and 
CSMI compared to sham mice for each genotype (Table 4 and Figure 4).  We also found 
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that estrogen supplementation in WT mice led to a significant increase in Ct.Th, Ct.Ar 
compared to either WT sham mice or OVX mice, but sham and OVX were not different 
from each other.  In contrast, in Pyk2 KO mice had significantly higher Ct.Th, Ct.Ar, and 
CSMI than WT for OVX and sham but Pyk2 and WT did not have significantly different, 
Ct.Th, Ct.Ar, or CSMI for OVX+E2 (Table 3).   
We also examined if there was any change in the difference (delta) between the 
OVX+E2 and OVX groups for Pyk2 KO and WT mice.  The results are shown in Table 
5. This data reveals that for cortical bone, the difference between Pyk2 KO and WT 
groups was significantly different (p<0.05) for Ct.Ar, Ct.Th and CSMI, but not for total 
bone perimeter and tissue perimeter.  However, WT mice showed the greater increase in 
cortical parameters following estrogen supplementation than Pyk2 KO mice. This 
suggests that in Pyk2 KO mice, cortical bone was more resistant to change in response to 
estrogen status than WT mice. 
In summary, when looking at overall cortical data, it appears that sham Pyk2 KO 
mice have greater cortical bone parameters compared to sham WT mice, and that cortical 
bone mass in Pyk2 KO mice is preserved in the presence of low estrogen (OVX) or high 
estrogen (OVX+E2), suggesting that Pyk2 may play a role in the maintenance of cortical 
bone mass.  
 
UTERINE WEIGHT AND CIRCULATING ESTRADIOL LEVELS 
 
The uterus is an estrogen-responsive organ and net uterine wet weight increases or 
decreases in parallel with changes in estrogen levels [60]. Therefore, to monitor the effect 
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of OVX and OVX+E2 in our mice, we measured uterine weight in Pyk2 KO and WT 
mice at the time of necropsy.   
   Overall, Pyk2 animals had higher uterine weights compared to WT.  When OVX 
was performed both mouse genotypes decreased in uterine weight and when 
supplemented with estrogen, the uterine weights of both mouse genotypes increased.   
 Changes in circulating serum levels of 17β-estradiol are an alternative measure of 
the efficacy of OVX and estrogen supplementation. Therefore, we collected whole blood 
at necropsy and measured 17β-estradiol levels in serum using a commercial enzyme-
linked immunosorbant assay (ELISA).  No differences were detected in estrogen levels 
between WT and Pyk2 KO mice receiving sham surgeries or OVX surgeries.  Although, 
estradiol levels were significantly higher in mice supplemented with estrogen, we found 
no difference in serum estradiol levels between Pyk2 OVX+E2 and WT OVX+E2 groups 
(Figure 6).  
 For both uterine weight and serum 17β-estradiol levels, the difference in the 
effects of estrogen supplementation (OVX+E2) compared to OVX mice was not 
statistically significant between Pyk2 KO and WT mice (see Table 5). 
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TABLES   
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Study group WT Pyk2 KO 
Sham 10 10 
OVX 10 9 
OVX + E2 11 10 
 
 
TABLE 1. Surgical groups for WT and Pyk2 KO mice 
 
A total of 31 WT mice and 29 Pyk2 KO mice at twelve weeks of age were used.  Mice 
received sham surgery, ovariectomy (OVX) plus placebo pellet, or OVX plus 17-β-
estradiol pellets (OVX+E2). 
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TABLE 2. Mean and SD data from micro-CT analyses mice. 
 
Calculated bone data for trabecular and cortical bone parameters. 
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TABLE 3:  Statistical Analysis of micro-CT data for WT and Pyk2 KO Mice 
Chart comparing mouse to mouse interactions between WT and Pyk2 KO mice. 
This chart shows comparisons between WT and Pyk2 KO mice to demonstrate difference 
in bone density parameters which can be attributed to the mouse genotype.  Darkened 
boxes indicate statistical significance (p-value < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Outcome Mouse Comparison All OVX OVX+E2 sham 
Trabecular ln(BVTV) Pyk2 vs. WT <.0001 <.0001 0.0216 <.0001 
 
ln(Tbth) Pyk2 vs. WT <.0001 <.0001 <.0001 <.0001 
 ln(Tb#) Pyk2 vs. WT <.0001 0.0002 0.9976 0.0001 
Cortical Ct. Th Pyk2 vs. WT   0.0405 0.7876 0.0474 
 
rank(T. Ar) Pyk2 vs. WT <.0001 0.0001 0.9939 <.0001 
 
rank(B. Ar) Pyk2 vs. WT <.0001 <.0001 0.9982 <.0001 
 
ln(CSMI 
polar) Pyk2 
vs. 
WT <.0001 0.0049 0.9764 0.0004 
  
Endocortical 
Perimeter Pyk2 
vs. 
WT <.0001       
Non-Bone 
Uterine 
Weight Pyk2 
vs. 
WT 0.0371 
     Estrogen Pyk2 vs. WT 0.7515       
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p-values 
Bone Outcome Surgery Comparison All Pyk2 WT 
Trabecular ln(BVTV) OVX vs. OVX+E2 <.0001 <.0001 <.0001 
  
OVX vs. sham 0.0074 0.1472 0.3780 
    OVX+E2 vs. sham <.0001 <.0001 <.0001 
Trabecular ln(Tbth) OVX vs. OVX+E2 <.0001 <.0001 <.0001 
  
OVX vs. sham 0.1385 0.4592 0.9445 
    OVX+E2 vs. sham <.0001 <.0001 <.0001 
Trabecular ln(Tb#) OVX vs. OVX+E2 <.0001 <.0001 <.0001 
  
OVX vs. sham 0.0135 0.2347 0.4154 
    OVX+E2 vs. sham <.0001 0.0002 <.0001 
Cortical Ct. Th OVX vs. OVX+E2 
 
0.7166 0.0095 
  
OVX vs. sham 
 
0.2608 0.5395 
    OVX+E2 vs. sham   0.7876 0.0115 
Cortical rank(T. Ar) OVX vs. OVX+E2 0.0518 0.9860 0.0015 
  
OVX vs. sham 0.7423 0.9906 0.9978 
    OVX+E2 vs. sham 0.2380 0.8000 0.0062 
Cortical rank(B. Ar) OVX vs. OVX+E2 0.0518 0.9747 0.0011 
  
OVX vs. sham 0.8003 0.9977 0.9973 
    OVX+E2 vs. sham 0.1991 0.8328 0.0049 
Cortical ln(MMI polar) OVX vs. OVX+E2 0.7374 0.9056 0.2709 
  
OVX vs. sham 0.8936 0.9813 1.0000 
    OVX+E2 vs. sham 0.9570 0.5081 0.2345 
        
Non-Bone 
Uterine 
Weight OVX vs. OVX+E2 <.0001 
  
  
OVX vs. sham <.0001 
      OVX+E2 vs. sham <.0001    
Non-Bone Estrogen OVX vs. OVX+E2 0.0045  
 
  
OVX vs. sham 0.9923  
     OVX+E2 vs. sham 0.0046    
 
TABLE 4. Statistical Analysis of effects of estrogen on WT and Pyk2 KO OVX 
mice.   
 
This chart shows comparisons between WT and Pyk2 KO mice surgical groups to assess 
the effects of estrogen bone density.  Darkened boxes denote statistical significance (p-
values < 0.05).   
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Statistical significance of difference (delta) between WT and Pyk2 KO mice 
Comparison of (OVX+E2 - OVX) for Pyk2 versus (OVX+E2 - OVX) for WT 
  Difference (SE) p-value 
Trabecular ln(BVTV) -0.63 (0.29) 0.0329 
Trabecular ln(Tb.Th) 0.21 (0.06) 0.0010 
Trabecular ln(Tb.N) -0.85 (0.27) 0.0027 
    
Cortical rank(T. Ar) -25.86 (7.73) 0.0015 
Cortical rank(B. Ar) -26.95 (7.74) 0.0010 
Cortical ln(CSMI polar) -0.24 (0.10) 0.0294 
Cortical Cortical Bone Perimeter -0.28 (0.41) 0.5027 
Cortical Tissue Perimeter -0.24 (0.13) 0.0766 
    
Non-Bone Uterine Weight 9.40 (19.03) 0.6234 
Non-Bone Estrogen -5.31 (15.78) 0.7396 
 
 
TABLE 5.   Differences in the effects of estrogen supplementation on trabecular 
and cortical bone parameters for WT versus Pyk2 KO mice.   
 
Comparison of the differences calculated between surgical groups and mouse genotypes.  
Table shows the difference between data groups for Pyk2 KO versus WT mice for the 
OVX+E2 minus OVX groups for all parameters.  The differences (delta) were found to 
be statistically significant between genotypes for BV/TV, Tb.Th, TbN (bigger difference 
for Pyk2 KO mice) and for cortical analysis of T.Ar, B.Ar and CSMI (bigger difference 
for WT mice) (p<0.05).   
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FIGURES   
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FIGURE 1.  Schematic illustration of the role of estrogen on bone remodeling.  
 
The pituitary gland secretes follicle-stimulating hormone (FSH) which stimulates 
estrogen secretion by the ovaries. Estrogens inhibit FSH secretion through negative 
feedback regulation mediated by the pituitary ER. After menopause, estrogen deficiency 
increases FSH secretion which causes the bone marrow and immune cells to release 
cytokines, interleukins (IL) and tumor necrosis factor (TNF).  These cause the osteoclasts 
to differentiate from hematopoietic stem cells.   In contrast,  estrogen and growth 
hormone (GH) from the pituitary gland cause the liver to release insulin-like growth 
factor 1 (IGF-1) which causes the osteoblasts to differentiate. [14] 
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A.   
 
B. 
 
FIGURE 2. Representative micro-CT images of trabecular bone in WT and Pyk2 
KO mice 
 
Micro-CT studies were performed on the distal femoral metaphysis.  Scans were acquired 
using an x-ray source set at 60kV over an angular range of 180 degrees (rotational steps 
of 0.7 degrees) with a 6 µm pixel size.  A.  Representation of region of interest used for 
analysis of trabecular bone.  B. Projection images of bone slices from each study group 
are shown and were generated by image reconstructed using standard Skyscan software. 
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FIGURE 3.  Micro-CT analysis of trabecular bone in WT and Pyk2 KO mice.   
 
Trabecular bone parameters were measured by micro-CT on WT and Pyk2 KO 16 week 
old mice.  A. Bone volume/total volume (BV/TV).  B.  Trabecular thickness (Tb.Th.).  C. 
Trabecular number (Tb.N.).  Results are mean ± SD from female mice (n=9 WT sham, 10 
WT OVX, 10 WT OVX+E2) (n=10 Pyk2 KO sham, 10 Pyk2 KO OVX, 10 Pyk2 KO 
OVX+E2).  p<0.05 using 2-way ANOVA for genotypes/groups (a-g).  The relative 
change in BV/TV for Pyk2 KO OVX+E2 (#) relative to OVX ($) or sham was 
significantly greater than the change in BV/TV calculated for WT mice (see D on next 
page). 
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FIGURE 4.  Effect of OVX and estrogen on cortical bone mass. 
 
Micro-CT analysis of cortical bone in WT and Pyk2 KO mice 4 weeks after surgery.  A. 
Cortical thickness (Ct.Th.). B. Mean total cross sectional area(Ct.Ar).  C. Mean polar 
moment of inertia (CSMI).   Graph C is shown on following page.  All graphs are mean ± 
SD. N=9 WT sham, 10 WT OVX, 10 WT OVX+E2.  N=10 Pyk2 KO sham, 10 Pyk2 KO 
OVX, 10 Pyk2 KO OVX+E2).  p<0.05 using 2-way ANOVA for genotypes/groups.  
Significance indicated by symbols “a-e”. C. Mean polar moment of inertia (CSMI). 
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A. Uteri from Pyk2 KO mice 
 
 
 
 
Mean ± SEM 
% change within genotype 
relative to sham ± SEM 
WT sham 70.8 ± 8.6 100  ±  12.1 
WT OVX 24.1 ± 3.1 34.0  ± 4.3 
WT OVX + E2 170.3  ± 12.5 240.5  ± 17.6 
   Pyk2 KO sham 108.7 ± 8.7 100  ± 8.0 
Pyk2 KO OVX 25.2 ± 5.3 23.2  ±  4.9 
Pyk2 KO OVX + E2 180.4 ± 15.8 166  ± 14.5 
 
FIGURE 5.  Effect of OVX and estrogen on uterine weight 
 
The uteri of Pyk2 KO and WT mice were harvested at the time of necropsy and weighed.  
A.  Representative photographs of uteri from Pyk2 KO mice.  B.  The average net wet 
weight of uteri (mg) ±  standard error of the mean (SEM) for each experimental group.  N 
=9 WT sham, 10 WT OVX, 10 WT OVX + E2.  N=10 Pyk2 KO sham, 10 Pyk2 KO 
OVX, 10 Pyk2 KO OVX+E2. p<0.05 using 2-way ANOVA for genotypes/groups as 
indicated (a-e).  Statistically significant differences in uterine weight were seen between 
WT and Pyk2 KO mice, and between sham and OVX +E2 groups.  C.  Percent (%) 
increase in uterine weight for WT and Pyk2 KO mice. Statistical significance denoted by 
asterisk. 
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FIGURE 6:  Serum estrogen levels in WT and Pyk2 KO mice.   
 
Blood sera from WT and Pyk2 KO mice were assayed for total estrogen levels by ELISA.  
The graph is mean ± SD of results.  For WT mice, n=9 sham, 10 OVX and 10 OVX+E2.  
For Pyk2 KO mice, n=10 sham, 10 OVX and 10 OVX+E2.  p<0.05 using 2-way 
ANOVA of genotypes/groups.  Statistical significance for multiple comparisons is 
indicated by “a-d”. 
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DISCUSSION 
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The fine balance between bone formation and resorption occurs by the carefully 
modulated interactions of osteoclasts and osteoblasts, and these interactions are 
influenced by many agents, including endocrine and paracrine factors.  Alterations in 
bone cells or the factors that regulate them can yield pathologic conditions of bone such 
as post-menopausal bone loss.  Declining estrogen levels during menopause yield both 
decreases in the osteoblast cell lineage and bone formation, as well as increases in 
osteoclast differentiation and bone-resorbing activity due to increased life-span.  Overall, 
this leads to a reduction in bone mass and consequently, osteoporosis which makes bones 
more susceptible to fracture.  Therefore, understanding the mechanisms by which bone 
loss occurs may yield more finely targeted therapeutic approaches to prevent bone loss 
and replace bone.     
Previous studies from our laboratory have revealed that Pyk2, a non-receptor 
tyrosine kinase, plays an important role in the regulation of osteoclasts and osteoblasts.  
In the current study, we found that female Pyk2 KO mice, which started with greater 
bone mass, had an overall higher bone mass after OVX than WT OVX mice.  Hence, the 
increase in high bone mass of Pyk2 KO mice would be predicted to provide some 
protective effect against some of the negative sequelae of bone loss, such as increased 
bone fragility.   In addition, we found that the Pyk2 KO mice were more responsive to 
estrogen supplementation than WT mice, resulting in a greater increase in bone mass 
following estrogen supplementation than WT mice.  These findings suggest that Pyk2 
regulates bone mass in part by modulating estrogen signaling cascades.  Although the 
molecular mechanism for the role of Pyk2 in estrogen signaling is still unknown, 
correlations can be drawn between our study and the study of Sims et al., (2002) using 
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single or double ER knockout mice (ERα, ERβ or ERαβ KO mice) [31].  It was reported 
that ERα and ERβ have compensatory actions in the skeleton of female mice and both 
receptors influence bone remodeling.  In female mice, deletion of ERα leads to an 
increase in trabecular bone volume.  However, female mice lacking ERβ exhibited a 
higher BV/TV levels than both WT and ERα KO mice.  Moreover, in female mice 
lacking both ERα and ERβ (double KO) BV/TV was lower than WT mice.  In contrast, 
the bone density of male mice is primarily affected by deletion of ERα [31].  In the Sims 
study, male mice lacking ERα had higher BV/TV levels than WT mice, while deletion of 
ERβ left bone unchanged and mice lacking both ERα and ERβ (double KO) had an 
intermediate bone phenotype that was higher than WT mice [31].   ERβ is expressed in 
trabecular bone and ERα is primarily expressed in cortical bone [29, 30].  Given that we 
found marked changes in trabecular bone volume in Pyk2 KO mice in response to 
estrogen, but little effect on cortical bone parameters, these findings suggest that Pyk2 
potentially acts downstream of ERβ signaling pathways in trabecular bone.  This is also 
supported by our unpublished findings which reveal that osteopetrosis (high bone mass) 
in Pyk2 KO mice was detected in female mice, but not male mice.   
As was shown in our study and previously reported [1, 3], Pyk2 KO mice have 
higher BV/TV, trabecular thickness, and trabecular number than WT mice.   Buckbinder 
et al. investigated the possible role of Pyk2 inhibitors in the protection of post-
menopausal bone loss.  OVX rats were injected for 21 days with either vehicle, a small 
molecule inhibitor of Pyk2 (PF-431396), or an anti-resorptive agent.  Micro-CT analysis 
of the distal femur of these rats revealed that the Pyk2 inhibitor preserved bone density in 
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OVX rats, compared to controls.  Consistent with this finding, our current studies reveal 
that Pyk2 KO mice have a higher BV/TV, trabecular thickness and trabecular number 
than WT mice.  However, we were unable to detect a statistical significant change in 
trabecular bone mass after OVX for either Pyk2 KO or WT mice, when compared to 
sham mice, most likely due to insufficient passage of time following OVX.  When 
supplemented with estrogen after OVX, we found that both Pyk2 KO mice and WT mice 
demonstrated a higher trabecular bone mass than sham or OVX mice of the same 
genotype.  Importantly, we also determined whether the difference (delta) between 
OVX+E2 and sham was different for Pyk2 KO and WT mice.  These findings revealed 
that the magnitude of the bone mass increase in estrogen-supplemented mice was greater 
for Pyk2 KO mice than WT mice, indicating they are more responsive to estrogen   
Pyk2 KO mice also demonstrated higher cortical bone volume parameters than 
WT mice when comparing OVX groups or sham groups.  However, cortical bone for 
either Pyk2 KO or WT mice did not show statistically significant changes in bone 
morphometric parameters when exposed to estrogen supplementation, suggesting cortical 
bone may be more resistant to hormonal changes.  Another possible explanation for the 
lack of changes in cortical bone after estrogen supplementation could be due to 
insufficient passage of time to allow for detectable changes in bone parameters.  Indeed 
other research groups have used 6 weeks post-OVX mice to study bone morphometrics, 
again suggesting additional time may have yielded more significant results [41]  Of 
interest, cortical bone changes in humans are detected several years after trabecular bone 
changes are noted [12]. 
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As a measure of the in vivo effects of estrogen, we examined uterine weights after 
necropsy.   Uterine weights were greater in Pyk2 KO mice than WT mice, implying basal 
gonadal dysfunction or changes in female sex-hormones in Pyk2 KO mice.  
Unexpectedly, we were unable to detect a difference in circulating estradiol levels in 
Pyk2 KO and WT sham mice, perhaps due to the limits of sensitivity of our estradiol 
assay.  Nevertheless, when both Pyk2 KO and WT mice were given estrogen 
supplementation, uterine weight increased in both mice groups, but no statistically 
significant difference between the WT and Pyk2 KO mice was detected.  Consistent with 
this latter finding, there were no significant differences in circulating estradiol levels 
between the WT and Pyk2 KO mice.  In both Pyk2 KO and WT mice, estrogen 
supplementation unexpectedly resulted in a supra-physiological level of serum estradiol. 
Although mice were given extended slow-release estrogen pellets, the high estradiol 
levels could be attributed to the timing of when the pellet actually released a bolus.   
The results of this study suggest a link between estrogen and the regulation of 
bone mass by Pyk2. In other unpublished studies, we also found that Pyk2 KO female 
mice have a higher bone mass than Pyk2 KO male mice, when compared to WT mice of 
the same sex, suggesting that ovarian dysfunction and estrogen levels may in part explain 
the high bone mass phenotype of Pyk2 KO female mice.   However, many questions still 
remain regarding the role of Pyk2 on estrogen signaling.  Future studies are planned to 
investigate if increasing the duration of time between OVX and necropsy will allow for 
greater changes in trabecular and cortical bone parameters, uterine weight, and estrodiol 
levels.  In addition, increasing the number of mice used in the study may clarify some 
results. Though we used estrogen supplementation doses reported in the literature, we 
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detected supra-physiologic levels of estradiol in OVX+E2 mice at necropsy. Therefore, in 
future studies, a lower dose of estrogen supplementation will be used and we will 
measure serum estrodiol levels weekly.  Histological analysis of our bone samples is also 
planned to assess how osteoclast and osteoblast numbers and bone turnover rate are 
affected by Pyk2 KO and estrogen status.  We anticipate estrogen supplementation would 
increase osteoblast numbers and differentiation and decrease osteoclast numbers by 
inhibiting osteoclast differentiation.  Because Pyk2 is expressed in neural and 
hematopoietic tissues, and other tissues that impact bone, many endocrine or paracrine 
factors may be influencing the results of the current study.  Future studies will also 
involve the use of conditional Pyk2 KO mice which lack Pyk2 in either osteoclasts, 
osteoblasts, or osteocytes.  This will allow us to better investigate the bone cell specific 
effect of Pyk2 in response to high and low levels of estrogen. 
In summary, our results demonstrate a strong connection between Pyk2 and the 
control of bone mass by estrogen in mice.  Furthermore, our studies suggest that Pyk2 
inhibitors in combination with estrogen supplementation may provide a new potential 
therapy to prevent the devastating effects of post-menopausal bone loss and osteoporosis.  
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SUMMARY AND CONCLUSIONS 
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This study was conducted to determine the role of Pyk2 on estrogen-regulated bone mass.  
We hypothesized that Pyk2 KO mice would be protected from bone loss associated with 
ovariectomy and that when supplemented with estrogen would have increased bone 
density compared to WT ovariectomized mice.  Twelve week old WT and Pyk2 KO mice 
were subject to sham surgery, OVX + placebo, and OVX + E2 pellet implantation.  Mice 
were sacrificed at 16 weeks of age, and micro-CT analysis of the distal femoral 
metaphysis was performed.  Bone was analyzed for BV/TV, trabecular number, 
trabecular thickness, cortical thickness, cortical cross-sectional bone area, endocortical 
perimeter, and mean polar moment of inertia.  Our results confirmed that Pyk2 KO mice 
had significantly higher bone volume than WT mice.  Pyk2 KO mice had greater bone 
volume compared to WT mice after ovariectomy and showed a greater increase in bone 
density after estrogen supplementation than WT mice.  Our studies did not show cortical 
bone changes seen in other published studies [61] however, this could be attributed to an 
inadequate amount of time between OVX and sacrifice.  In summary, our study revealed 
a connection between estrogen status and its effects on bone morphometrics in Pyk2 KO 
mice.  The clinical implications of these findings are that pharmacological strategies to 
inhibit Pyk2 may yield new approaches for the management of post-menopausal bone 
loss.   
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Abbreviation legend 
BV/TV bone volume to total volume 
CSMI polar cross-sectional moment of intertia 
Ct. Ar cortical area 
Ct. Th cortical thickness 
E2  estrogen 
ELISA enzyme-linked immunosorbant assay 
ER α estrogen receptor alpha 
ER β estrogen receptor beta 
FAK focal adhesion kinase 
FSH follicle stimulating hormone 
IGF 1 insulin-like growth factor 1 
KO knock out 
M-CSF macrophage colony stimulating factor 
micro-CT micro-computed tomography 
OPG osteoprotegerin 
OVX ovariectomized 
RANK L receptor activator of nuclear factor κβ 
ligand 
SERMS selective estrogen receptor modulators 
Tb.N trabecular number 
Tb.Th trabecular thickness 
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Pyk2:  Potential Regulator of Post-Menopausal Bone Loss 
H.W. LARGURA1,2*, P. ELENISTE2, S. HUANG2, S. LIU1, M. ALLEN3,   
A. BRUZZANITI2. 
 
1Indiana University School of Dentistry Department Orthodontics and Oral Facial 
Development, 2Indiana University School of Dentistry Department of Oral Biology,  
3Indiana University School of Medicine Department of Anatomy and Cell Biology,  
Indianapolis, Indiana, USA 
 
 
 Osteoporosis is a pathologic condition of bone, commonly found in post-
menopausal women, which occurs from an imbalance between bone formation and 
resorption.  Following menopause, the bone resorbing activity of osteoclasts exceeds 
bone formation by osteoblasts, resulting in decreased trabecular and cortical bone and a 
subsequent decrease in bone mass.  Reduced bone mass increases the risk of pathologic 
fracture of bones. Due to adverse effects associated with current treatment protocols for 
bone loss, alternative treatment modalities with reduced adverse effects are needed.   
Estrogen plays a role in maintaining balance in the bone remodeling cycle by 
controlling remodeling activation, osteoblast and osteoclast numbers, and their respective 
effectiveness in formation and resorption.  With declining estrogen levels, this elegantly 
balanced interaction is altered and bone resorption exceeds bone formation, resulting in 
bone loss and increased bone fragility.   
Pyk2 is a protein tyrosine kinase that plays an important role in regulating bone 
resorption by osteoclasts, as well as osteoblast proliferation and differentiation.  Deletion 
of the Pyk2 gene in mice leads to an increase in bone mass, in part due to dysfunctional 
osteoclast and osteoblast activity.  In this study, we examined the role of Pyk2 in the 
effects of estrogen on bone mass.  We used wild type (WT) and Pyk2 knock-out (KO) 
52 
 
mice that had been ovariectomized (OVX) and treated with or without estrogen (E2)-
releasing pellets.  Control mice included sham OVX surgery receiving placebo pellet.  
We found that deletion of Pyk2 conferred increased bone mass in sham, OVX and 
OVX+E2 mice. In addition, Pyk2 KO mice supplemented with 17β−estradiol exhibited a 
marked increase in bone volume/trabecular volume, trabecular number, and trabecular 
thickness, but not cortical bone parameters compared to WT mice.  Results of this study 
provide evidence for the role of Pyk2 in the effects of estrogen on bone mass.  
Understanding the role of Pyk2 in bone could lead to the development of new 
pharmaceutical targets for the treatment of bone loss associated with osteoporosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CURRICULUM VITAE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heather W. Largura 
 
Education 
• Orthodontics Residency, July 2011-present, IU School of Dentistry, 
Indianapolis, IN. 
• AEGD:  1999-2000, United States Air Force, Scott AFB, Belleville, IL 
• DDS:  1995-1999, Indiana University School of Dentistry, Indianapolis, 
IN 
• BS Biology:  1989-2003, Indiana University, Bloomington, IN 
 
Professional Experience 
• Research Volunteer, 2010-2011, Department of Oral Biology, IU 
School of Dentistry, Indianapolis, IN. 
• Independent Contractor, 2008-2011, MiraVista Diagnostics, 
Indianapolis, IN. 
• Temporary Dentist, 2009-2011, Dental Medical Support Services, 
Indianapolis, IN. 
• Dentist, 2004- 2006, Marion County Health Department, Indianapolis, 
IN. 
• Temporary Dentist, 2003- 2004, Dental Support Services, Indianapolis, 
IN. 
• Dentist, 2000- 2003, United States Air Force, RAF Lakenheath AFB, 
Lakenheath, England.   
• AEGD Resident, 1999- 2000, United States Air Force, Scott Air Force 
Base, Belleville, IL. 
• Laboratory Technician, 1993- 1995, Histoplasmosis Reference 
Laboratory, Indianapolis, IN. 
 
Recognitions and Achievements: 
• Dean’s Silver Award for National Board Scores 
• Dean’s List throughout dental school 
• Graduated with Distinction (graduated within the top 10) 
• Omicron Kappa Upsilon Honor Dental Society 
• HPSP Scholarship Recipient, USAF 
• Air Force Commendation Medal, Meritorious Service, 2000-2003 
• Junior Officer of the Quarter, USAF 
 
Professional Organizations: 
• American Association of Orthodontists 
• American Dental Association 
 
